Cancer Biomarkers

A harm biomarker suggests a substance or methodology that is normal for the proximity of illness in the body. A biomarker may be an iota produced by a tumor or a specific response of the body to the proximity of sickness. Inherited, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for sickness investigation, surmise, and the investigation of ailment transmission. Ideally, such biomarkers can be tried in non-rudely assembled biofluids like blood or serum. The worldwide malignant growth biomarkers market is represented USD 10.31 billion of every 2016 and is required to develop at a CAGR of 12.2% to USD 20.48 billion by 2022 during the figure time frame.

• AFP (Liver Cancer)
• BRCA1/BRCA2 (Breast/Ovarian Cancer)
• BRAF V600E (Melanoma/Colorectal Cancer)
• EGFR (Non-small-cell lung carcinoma)
• BCR-ABL (Chronic Myeloid Leukemia)